Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance

Although much progress has been made in cancer treatment, the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signatures of radioresistant cancer cells still need to be clarified. In this regard, we discovered that breast, bladder, lung, neuroglioma, and prostat...

Full description

Bibliographic Details
Main Authors: Luca Tirinato, Maria Grazia Marafioti, Francesca Pagliari, Jeannette Jansen, Ilenia Aversa, Rachel Hanley, Clelia Nisticò, Daniel Garcia-Calderón, Geraldine Genard, Joana Filipa Guerreiro, Francesco Saverio Costanzo, Joao Seco
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2021-09-01
Series:eLife
Subjects:
Online Access:https://elifesciences.org/articles/72943
id doaj-875cfacd9fc346f3be09bad933aa1257
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Luca Tirinato
Maria Grazia Marafioti
Francesca Pagliari
Jeannette Jansen
Ilenia Aversa
Rachel Hanley
Clelia Nisticò
Daniel Garcia-Calderón
Geraldine Genard
Joana Filipa Guerreiro
Francesco Saverio Costanzo
Joao Seco
spellingShingle Luca Tirinato
Maria Grazia Marafioti
Francesca Pagliari
Jeannette Jansen
Ilenia Aversa
Rachel Hanley
Clelia Nisticò
Daniel Garcia-Calderón
Geraldine Genard
Joana Filipa Guerreiro
Francesco Saverio Costanzo
Joao Seco
Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
eLife
lipid droplets
radioresistance
iron metabolism
ferritin heavy chain
cancer
author_facet Luca Tirinato
Maria Grazia Marafioti
Francesca Pagliari
Jeannette Jansen
Ilenia Aversa
Rachel Hanley
Clelia Nisticò
Daniel Garcia-Calderón
Geraldine Genard
Joana Filipa Guerreiro
Francesco Saverio Costanzo
Joao Seco
author_sort Luca Tirinato
title Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
title_short Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
title_full Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
title_fullStr Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
title_full_unstemmed Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
title_sort lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
publisher eLife Sciences Publications Ltd
series eLife
issn 2050-084X
publishDate 2021-09-01
description Although much progress has been made in cancer treatment, the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signatures of radioresistant cancer cells still need to be clarified. In this regard, we discovered that breast, bladder, lung, neuroglioma, and prostate 6 Gy X-ray resistant cancer cells were characterized by an increase of lipid droplet (LD) number and that the cells containing highest LDs showed the highest clonogenic potential after irradiation. Moreover, we observed that LD content was tightly connected with the iron metabolism and in particular with the presence of the ferritin heavy chain (FTH1). In fact, breast and lung cancer cells silenced for the FTH1 gene showed a reduction in the LD numbers and, by consequence, became radiosensitive. FTH1 overexpression as well as iron-chelating treatment by Deferoxamine were able to restore the LD amount and RR. Overall, these results provide evidence of a novel mechanism behind RR in which LDs and FTH1 are tightly connected to each other, a synergistic effect that might be worth deeply investigating in order to make cancer cells more radiosensitive and improve the efficacy of radiation treatments.
topic lipid droplets
radioresistance
iron metabolism
ferritin heavy chain
cancer
url https://elifesciences.org/articles/72943
work_keys_str_mv AT lucatirinato lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT mariagraziamarafioti lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT francescapagliari lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT jeannettejansen lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT ileniaaversa lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT rachelhanley lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT clelianistico lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT danielgarciacalderon lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT geraldinegenard lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT joanafilipaguerreiro lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT francescosaveriocostanzo lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
AT joaoseco lipiddropletsandferritinheavychainadevilishliaisoninhumancancercellradioresistance
_version_ 1716839499119460352
spelling doaj-875cfacd9fc346f3be09bad933aa12572021-10-07T09:26:24ZengeLife Sciences Publications LtdeLife2050-084X2021-09-011010.7554/eLife.72943Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistanceLuca Tirinato0https://orcid.org/0000-0001-9826-2129Maria Grazia Marafioti1Francesca Pagliari2https://orcid.org/0000-0002-5547-222XJeannette Jansen3https://orcid.org/0000-0002-8625-3978Ilenia Aversa4Rachel Hanley5https://orcid.org/0000-0002-2627-1146Clelia Nisticò6https://orcid.org/0000-0002-0787-9527Daniel Garcia-Calderón7Geraldine Genard8https://orcid.org/0000-0002-9495-0335Joana Filipa Guerreiro9https://orcid.org/0000-0003-1960-603XFrancesco Saverio Costanzo10Joao Seco11https://orcid.org/0000-0002-9458-2202Biomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany; Experimental and Clinical Medicine Department, University Magna Graecia of Catanzaro, Catanzaro, ItalyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany; Experimental and Clinical Medicine Department, University Magna Graecia of Catanzaro, Catanzaro, ItalyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, GermanyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany; Department of Physics and Astronomy, Heidelberg University, Im Neuenheimer Feld, Heidelberg, GermanyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany; Experimental and Clinical Medicine Department, University Magna Graecia of Catanzaro, Catanzaro, ItalyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, GermanyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany; Experimental and Clinical Medicine Department, University Magna Graecia of Catanzaro, Catanzaro, ItalyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany; Department of Physics and Astronomy, Heidelberg University, Im Neuenheimer Feld, Heidelberg, GermanyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, GermanyCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalExperimental and Clinical Medicine Department, University Magna Graecia of Catanzaro, Catanzaro, ItalyBiomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany; Department of Physics and Astronomy, Heidelberg University, Im Neuenheimer Feld, Heidelberg, GermanyAlthough much progress has been made in cancer treatment, the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signatures of radioresistant cancer cells still need to be clarified. In this regard, we discovered that breast, bladder, lung, neuroglioma, and prostate 6 Gy X-ray resistant cancer cells were characterized by an increase of lipid droplet (LD) number and that the cells containing highest LDs showed the highest clonogenic potential after irradiation. Moreover, we observed that LD content was tightly connected with the iron metabolism and in particular with the presence of the ferritin heavy chain (FTH1). In fact, breast and lung cancer cells silenced for the FTH1 gene showed a reduction in the LD numbers and, by consequence, became radiosensitive. FTH1 overexpression as well as iron-chelating treatment by Deferoxamine were able to restore the LD amount and RR. Overall, these results provide evidence of a novel mechanism behind RR in which LDs and FTH1 are tightly connected to each other, a synergistic effect that might be worth deeply investigating in order to make cancer cells more radiosensitive and improve the efficacy of radiation treatments.https://elifesciences.org/articles/72943lipid dropletsradioresistanceiron metabolismferritin heavy chaincancer